Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers

Journal of Clinical Oncology

Volumn 36, Issue 17, 2018, Pages 1685-1694

  Teo, Min Yuen ^a   Seier, Kenneth ^a   Ostrovnaya, Irina ^a   Regazzi, Ashley M ^a   Kania, Brooke E ^a   Moran, Meredith M ^a   Cipolla, Catharine K ^a   Bluth, Mark J ^a   Chaim, Joshua ^a   Al Ahmadie, Hikmat ^a   Snyder, Alexandra ^a   Carlo, Maria I ^a   Solit, David B ^a   Berger, Michael F ^a   Funt, Samuel ^a   Wolchok, Jedd D ^a   Iyer, Gopa ^a   Bajorin, Dean F ^a   Callahan, Margaret K ^a   Rosenberg, Jonathan E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; CARBOPLATIN; CISPLATIN; DNA; HEMOGLOBIN; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; DNA DAMAGE AND REPAIR GENE; DNA DAMAGE RESPONSE; DNA REPAIR; EXCISION REPAIR; EXON; FEMALE; FOLLOW UP; GENE DELETION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; KIDNEY PELVIS CARCINOMA; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; ONCOGENE; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; URETER CARCINOMA; URETHRA CARCINOMA; VISCERAL METASTASIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DNA DAMAGE; GENETICS; IMMUNOLOGY; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; URINARY TRACT TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROGRESSION-FREE SURVIVAL; PROSPECTIVE STUDIES; UROLOGIC NEOPLASMS;

EID: 85047189570     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.75.7740     Document Type: Article

References (43)

1. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
2. Sharma P, Callahan MK, Bono P, et al: Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17:1590-1598, 2016
3. Sharma P, Retz M, Siefker-Radtke A, et al: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312-322, 2017
4. Powles T, O’Donnell PH, Massard C, et al: Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma. J Clin Oncol 35, 2017 (suppl; abstr 286)
5. Apolo AB, Infante JR, Balmanoukian A, et al: Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol 35:2117-2124, 2017
6. Bellmunt J, de Wit R, Vaughn DJ, et al: Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015-1026, 2017
7. Balar AV, Galsky MD, Rosenberg JE, et al: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet 389:67-76, 2017
8. Rizvi NA, Hellmann MD, Snyder A, et al: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124-128, 2015
9. Rosenberg JE, Petrylak DP, Van Der Heijden MS, et al: PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). J Clin Oncol 34, 2016 (suppl; abstr 104)
10. Snyder A, Nathanson T, Funt SA, et al: Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Med 14:e1002309, 2017
11. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-322, 2014
12. Iyer G, Balar AV, Milowsky MI, et al: Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC). J Clin Oncol 34, 2016 (suppl; abstr 5011)
13. Teo MY, Bambury RM, Zabor EC, et al: DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Cancer Res 23:3610-3618, 2017
14. Van Allen EM, Mouw KW, Kim P, et al: Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4:1140-1153, 2014
15. Yap KL, Kiyotani K, Tamura K, et al: Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res 20:6605-6617, 2014
16. Galsky MD, Uzilov AV, McBride RB, et al: DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC). J Clin Oncol 35, 2017 (suppl; abstr 300)
17. McBride RB, Patel VG, Collazo Lorduy A, et al: Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs). J Clin Oncol 34, 2016 (suppl; abstr 4538)
18. Liu D, Plimack ER, Hoffman-Censits J, et al: Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2:1094-1096, 2016
19. Plimack ER, Dunbrack RL, Brennan TA, et al: Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68:959-967, 2015
20. Bellmunt J, Choueiri TK, Fougeray R, et al: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850-1855, 2010
21. Cheng DT, Mitchell TN, Zehir A, et al: Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17:251-264, 2015
22. Zehir A, Benayed R, Shah RH, et al: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med, 23:703-713, 2017
23. Schrader KA, Cheng DT, Joseph V, et al: Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol 2:104-111, 2016 [Erratum: JAMA Oncol 2:279, 2016]
24. Forbes SA, Beare D, Boutselakis H, et al: COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res 45:D777-D783, 2017
25. Chang MT, Asthana S, Gao SP, et al: Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Bio-technol 34:155-163, 2016
26. Memorial Sloan Kettering Cancer Center: Cancer Hotspots, 2017. http://cancerhotspots.org/#/home
27. Chakravarty D, Gao J, Phillips SM, et al: OncoKB: A precision oncology knowledge base. JCO Precis Oncol 2017:1-16, 2017
28. Memorial Sloan Kettering Cancer Center: OncoKB: Precision Oncology Knowledge Base. http://oncokb.org
29. Johnston JJ, Rubinstein WS, Facio FM, et al: Secondary variants in individuals undergoing exome sequencing: Screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 91:97-108, 2012
30. Shaag A, Walsh T, Renbaum P, et al: Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 14: 555-563, 2005
31. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
32. Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409-413, 2017
33. Food and Drug Administration: FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication, 2017 https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm560040.htm
34. Hugo W, Zaretsky JM, Sun L, et al: Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35-44, 2016 [Erratum: Cell 168:542, 2017]
35. Tumeh PC, Harview CL, Yearley JH, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571, 2014
36. Mouw KW, Goldberg MS, Konstantinopoulos PA, et al: DNA damage and repair biomarkers of immunotherapy response. Cancer Discov 7:675-693, 2017
37. Ahn J, Barber GN: Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. Curr Opin Immunol 31:121-126, 2014
38. Li T, Cheng H, Yuan H, et al: Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. Sci Rep 6:19049, 2016
39. Deng L, Liang H, Xu M, et al: STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41:843-852, 2014
40. Wang H, Hu S, Chen X, et al: cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc Natl Acad Sci U S A 114:1637-1642, 2017
41. Härtlova A, Erttmann SF, Raffi FA, et al: DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 42:332-343, 2015
42. Parkes EE, Walker SM, Taggart LE, et al: Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst 109:109, 2016
43. Fu J, Kanne DB, Leong M, et al: STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med 7: 283ra52, 2015